Clinical Trial

A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU-Lung02)

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This trial is a registered phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with locally advanced or metastatic EGFR wild-type non-small cell lung cancer after failure of anti-PD-1/PD-L1 monoclonal antibodies and platinum-based chemotherapy.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2024-04-19; most recent amendment 2026-04-15.
Status change: Recruiting → Active, Not Recruiting 2026-04-07
Status change: Not Yet Recruiting → Recruiting 2024-06-04
Trial Details
NCT Number NCT06382129
Lead Sponsor Sichuan Baili Pharmaceutical Co., Ltd.
Collaborators: Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Conditions Non-small Cell Lung Cancer
Enrollment 698 participants
Start Date 2024-05-17
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-04-17